The approval by the DCGI comes following recommendations by the Subject Expert Committee (SEC) on Covid-19 of the Central Drugs Standard Control Organisation(CDSCO)
Covaxin was earlier approved for children 12-18 years of age
Tc99m tilmanocept is designed for the precise identification of lymph nodes that drain from a primary tumor, which have the highest probability of harboring cancer
Biolexis will also leverage the capabilities of Strides Group for launching this vaccine across regions where the group has a deep market presence and established relationships
Feedback and remarks of the industry and stakeholders are invited till the 25th of March 2022
Amit Jaju, Senior Managing Director, India in an interview with Thomas C Thottathil outlined the steps Indian pharma companies should follow to be compliant with global regulatory requirements
The DCGI has already approved Covovax for restricted use in emergency situations in adults on December 28th 2021
Paxlovid consists of nirmatrelvir, which inhibits a SARS-CoV-2 protein to stop the virus from replicating, and ritonavir, which slows down nirmatrelvir’s breakdown to help it remain in the body for a longer period at higher concentrations
This is the ninth Covid-19 vaccine approved in India
The recommendations have been sent to the Drugs Controller General of India (DCGI) for the final approval
Subscribe To Our Newsletter & Stay Updated
